ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 452-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The…
Denosumab Dosing Delays Tied to Increased Fracture Risk
NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…
FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis
HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…
Ixekizumab May Improve Pain & Sexual Health in Patients with Genital Psoriasis
Research has shown ixekizumab improves pain and the sexual health of patients with genital psoriasis…
FDA Approves Canakinumab for Adult-Onset Still’s Disease
Canakinumab, an interleukin (IL) 1 blocker, can now be prescribed to treat patients with active Still’s disease and adult-onset Still’s disease (AOSD)…
Interleukin 17 Inhibitors Promising in Ankylosing Spondylitis Patients
In patients with active ankylosing spondylitis, IL-17 inhibitors have produced favorable responses, according to recent research…
Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19
COVID-19 Global Alliance registry and other data on rheumatic disease patients with COVID-19 were presented…
Apremilast Promising for Plaque Psoriasis
Apremilast has been shown to improve the signs and symptoms of mild to moderate plaque psoriasis in adults, according to new research…
Biosimilar Prescribing Habits in the VA & Academic Settings
In a new study, Baker et al. examined reference product and biosimilar orders, comparing data from a Veterans Affairs Medical Center (VAMC) to those from an academic medical center…
ABX464 in Phase 2a Trials for RA
Research is examining the safety and tolerability of two different doses of ABX464 in patients with moderate to severe active RA…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 126
- Next Page »